J&J bispecific combo delivers 89% PFS benefit in myeloma
Johnson & Johnson's bispecific antibody combination delivers an 89% progression-free survival benefit in a multiple myeloma trial.
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation operating through two business segments: Innovative Medicine and MedTech. It is one of the world's largest and most diversified healthcare companies, with products spanning oncology, immunology, neuroscience, cardiovascular, and surgical technologies.
Johnson & Johnson's bispecific antibody combination delivers an 89% progression-free survival benefit in a multiple myeloma trial.
Chairman and Chief Executive Officer